A precision oncology company rooted in science and innovation, pioneering the development of unique cancer therapies. https://xitter.cf/t.co/yiezNZmnc9
Joined February 2021
- Tweets176
- Following136
- Followers91
- Likes17
On Monday, Fore Bio joined the Precision Oncology: Developing Next-Gen Approaches panel at the Goldman Sachs Healthcare Private Company Conference. Thank you to Goldman Sachs for hosting. #PrecisionOncology #Oncology
We are excited to be attending the Wells Fargo 21st Annual Healthcare Conference (Sept. 8) and the Morgan Stanley 24th Annual Global Healthcare Conference (Sept. 15), where we will give a corporate presentation. Reach out to connect with our team!
Today, we announced a positive outcome from the planned interim efficacy analysis of the Fusions Basket in the FORTE study evaluating plixorafenib in BRAF-altered advanced solid tumors. The IDMC recommends the study continue as planned. Learn more: bit.ly/4xpXEOq
We’re honored to see our $67.4 M Series D-2 Extension financing recognized on the @Nasdaq tower. This milestone accelerates our work advancing plixorafenib, our next-generation BRAF inhibitor, for patients with BRAF-altered cancers.
We are pleased to announce the closing of an upsized financing, raising $67.4 million. We’re grateful for the confidence from new and all our existing investors as we advance plixorafenib to patients in need of improved therapeutic options. Learn more:bit.ly/4yai7Yl
We’re excited to attend #ISPNO2026. Stop by Booth 21 or check out our Poster #225 on plixorafenib and the FORTE study. See you there! #BRAF
We’re on the ground in New York at the Jefferies 2026 Global Healthcare Conference.
To request a meeting with management, please reach out to [email protected]
#ForeBio
Fore Bio will participate in the Stifel 2026 Virtual Targeted Oncology Forum on May 19 and Jefferies 2026 Global Healthcare Conference on June 2. To request a meeting with management, please contact Argot Partners ([email protected]).
Learn more: bit.ly/4uDbJGs
We’re proud that the FDA has recently granted BTD to plixorafenib for the treatment of adult patients with #HGG. We look forward to continuing collaboration with the FDA to further advance plixorafenib and our FORTE basket trial in several types of BRAF altered malignancies.
#BreakthroughTherapy Designation granted to plixorafenib for the treatment of #HGG reinforces our commitment to bringing plixorafenib to patients. Thank you to our team and partners who are working towards bringing this treatment to patients as quickly as possible.
FDA granted Breakthrough Therapy Designation to plixorafenib for the treatment of adult patients with BRAF V600E-mutated high-grade glioma. This recognizes plixorafenib’s potential to provide substantial improvement over available therapies.
Learn more: bit.ly/4sebMqL
We look forward to connecting with industry leaders and innovators during #JPM2026.
Please contact Argot Partners ([email protected]) to schedule one-on-one meetings with management.
See you in San Francisco!
Wishing you a joyful holiday season from all of us at Fore Bio. We’re grateful for the continued support and collaboration that made this year a success. Here's to a healthy and impactful year ahead!
Our CEO, Bill, recently joined #TheBioCenturyShow. Drawing on his extensive biotech and oncology experience, Bill shares why plixorafenib is uniquely positioned to address critical unmet needs in BRAF-driven tumors. Tune in: bit.ly/4rKSgD1
A sincere thank you to Dr. Eric Sherman for joining our KOL roundtable discussion on plixorafenib, and for providing his insights into its potential role in treating patients with BRAF-driven tumors.
Listen to a replay of the webcast here: bit.ly/3Ja2zPM
A huge thank you to Dr. Macarena de la Fuente for her expertise and insights during our recent KOL roundtable discussion on plixorafenib and its potential to disrupt the BRAF market for the benefit of patients.
Listen to a replay of the webcast here: bit.ly/3Ja2zPM
